GL Pharm Tech（A204840）株式概要GL Pharm Tech Corp.は、韓国の製薬会社にジェネリック医薬品とインクリメンタリー・モディファイド・ドラッグ（IMD）製剤技術を提供している。 詳細A204840 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性1/6配当金0/6報酬過去5年間の収益は年間26.9%増加しました。 リスク分析キャッシュランウェイが1年未満である 意味のある時価総額がありません ( ₩72B )すべてのリスクチェックを見るA204840 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₩Current Price₩930.0079.4% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-7b107b2016201920222025202620282031Revenue ₩107.5bEarnings ₩15.7bAdvancedSet Fair ValueView all narrativesGL Pharm Tech Corp. 競合他社Enzychem LifesciencesSymbol: KOSDAQ:A183490Market cap: ₩76.4bJin Yang PharmaceuticalSymbol: KOSDAQ:A007370Market cap: ₩57.6bKukje PharmaSymbol: KOSE:A002720Market cap: ₩81.5bWITHUS PHARMACEUTICALLTDSymbol: KOSDAQ:A330350Market cap: ₩97.7b価格と性能株価の高値、安値、推移の概要GL Pharm Tech過去の株価現在の株価₩930.0052週高値₩1,352.0052週安値₩893.00ベータ0.461ヶ月の変化-12.26%3ヶ月変化-14.13%1年変化-28.24%3年間の変化8.14%5年間の変化-39.61%IPOからの変化-86.50%最新ニュースお知らせ • Mar 13GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2026GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 257, saemaeul-ro, bundang-gu, gyeonggi-do, seongnam South Korea分析記事 • Dec 01GL Pharm Tech (KOSDAQ:204840) Has A Somewhat Strained Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Reported Earnings • Nov 12Third quarter 2025 earnings released: EPS: ₩2.00 (vs ₩2.00 loss in 3Q 2024)Third quarter 2025 results: EPS: ₩2.00 (up from ₩2.00 loss in 3Q 2024). Revenue: ₩9.53b (up 104% from 3Q 2024). Net income: ₩132.8m (up ₩250.4m from 3Q 2024). Profit margin: 1.4% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Sep 23GL Pharm Tech Corp.'s (KOSDAQ:204840) P/S Still Appears To Be ReasonableWhen you see that almost half of the companies in the Pharmaceuticals industry in Korea have price-to-sales ratios (or...New Risk • Aug 27New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 1.1x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risk Market cap is less than US$100m (₩90.2b market cap, or US$64.7m).Reported Earnings • May 16First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: ₩7.84b (up 34% from 1Q 2024). Net income: ₩24.1m (up ₩1.66b from 1Q 2024). Profit margin: 0.3% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.最新情報をもっと見るRecent updatesお知らせ • Mar 13GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2026GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 257, saemaeul-ro, bundang-gu, gyeonggi-do, seongnam South Korea分析記事 • Dec 01GL Pharm Tech (KOSDAQ:204840) Has A Somewhat Strained Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Reported Earnings • Nov 12Third quarter 2025 earnings released: EPS: ₩2.00 (vs ₩2.00 loss in 3Q 2024)Third quarter 2025 results: EPS: ₩2.00 (up from ₩2.00 loss in 3Q 2024). Revenue: ₩9.53b (up 104% from 3Q 2024). Net income: ₩132.8m (up ₩250.4m from 3Q 2024). Profit margin: 1.4% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Sep 23GL Pharm Tech Corp.'s (KOSDAQ:204840) P/S Still Appears To Be ReasonableWhen you see that almost half of the companies in the Pharmaceuticals industry in Korea have price-to-sales ratios (or...New Risk • Aug 27New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 1.1x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risk Market cap is less than US$100m (₩90.2b market cap, or US$64.7m).Reported Earnings • May 16First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: ₩7.84b (up 34% from 1Q 2024). Net income: ₩24.1m (up ₩1.66b from 1Q 2024). Profit margin: 0.3% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.分析記事 • Apr 23Revenues Tell The Story For GL Pharm Tech Corp. (KOSDAQ:204840) As Its Stock Soars 45%The GL Pharm Tech Corp. ( KOSDAQ:204840 ) share price has done very well over the last month, posting an excellent gain...New Risk • Apr 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩5.0b free cash flow). Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (₩109.2b market cap, or US$76.8m).Reported Earnings • Mar 22Full year 2024 earnings released: ₩31.00 loss per share (vs ₩60.00 loss in FY 2023)Full year 2024 results: ₩31.00 loss per share (improved from ₩60.00 loss in FY 2023). Revenue: ₩26.0b (flat on FY 2023). Net loss: ₩2.34b (loss narrowed 38% from FY 2023). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 4% per year.お知らせ • Mar 13GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2025GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 257, saemaeul-ro, bundang-gu, gyeonggi-do, seongnam South KoreaNew Risk • Aug 23New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩4.8b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩4.8b free cash flow). Minor Risks Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (₩80.8b market cap, or US$60.4m).分析記事 • Jul 23Is GL Pharm Tech (KOSDAQ:204840) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...New Risk • Apr 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩101.2b market cap, or US$73.6m).New Risk • Mar 30New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩104.5b market cap, or US$77.7m).Reported Earnings • Mar 21Full year 2023 earnings released: ₩60.00 loss per share (vs ₩13.00 loss in FY 2022)Full year 2023 results: ₩60.00 loss per share (further deteriorated from ₩13.00 loss in FY 2022). Revenue: ₩26.0b (up 56% from FY 2022). Net loss: ₩3.75b (loss widened 374% from FY 2022). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 07W Science Co., Ltd. completed the acquisition of 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity FundW Science Co., Ltd. agreed to acquire a 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity Fund for KRW 15.77 billion on September 14, 2023. W Science Co., Ltd. entered into an agreement to acquire 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity Fund, KAIS Inc and Hoon-sik Wang for KRW 15.77 billion on February 28, 2024. The offer per share is KRW 1700 per share. The scheduled transaction closing date is April 29, 2024. W Science Co., Ltd. completed the acquisition of 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity Fund on March 6, 2024.お知らせ • Mar 06GL Pharm Tech Corp. announced that it has received KRW 9.199999458 billion in funding from W Science Co., Ltd.On March 6, 2024, GL Pharm Tech Corp. closed the transaction.分析記事 • Mar 01Market Participants Recognise GL Pharm Tech Corp.'s (KOSDAQ:204840) Revenues Pushing Shares 25% HigherGL Pharm Tech Corp. ( KOSDAQ:204840 ) shares have had a really impressive month, gaining 25% after a shaky period...Reported Earnings • Nov 15Third quarter 2023 earnings released: ₩15.00 loss per share (vs ₩5.00 loss in 3Q 2022)Third quarter 2023 results: ₩15.00 loss per share (further deteriorated from ₩5.00 loss in 3Q 2022). Revenue: ₩7.69b (up 64% from 3Q 2022). Net loss: ₩963.6m (loss widened 280% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.New Risk • Nov 15New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩3.1b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩3.1b free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (₩78.1b market cap, or US$59.9m).New Risk • Jul 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩67.7b market cap, or US$52.6m).Reported Earnings • May 14First quarter 2023 earnings released: ₩10.00 loss per share (vs ₩42.00 loss in 1Q 2022)First quarter 2023 results: ₩10.00 loss per share (improved from ₩42.00 loss in 1Q 2022). Revenue: ₩5.11b (up 103% from 1Q 2022). Net loss: ₩598.2m (loss narrowed 73% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 08Third quarter 2022 earnings released: ₩5.00 loss per share (vs ₩5.00 loss in 3Q 2021)Third quarter 2022 results: ₩5.00 loss per share (in line with 3Q 2021). Revenue: ₩4.70b (up 88% from 3Q 2021). Net loss: ₩306.2m (loss narrowed 78% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.分析記事 • Mar 30Would GL Pharm Tech (KOSDAQ:204840) Be Better Off With Less Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Dec 15The GL Pharm Tech (KOSDAQ:204840) Share Price Is Up 50% And Shareholders Are Holding OnPassive investing in index funds can generate returns that roughly match the overall market. But one can do better than...Is New 90 Day High Low • Dec 02New 90-day high: ₩1,190The company is up 17% from its price of ₩1,015 on 03 September 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.お知らせ • Nov 25GL Pharm Tech Corp. announced that it expects to receive KRW 4.5 billion in funding from Ideal Priavate Equity 1 Co., Ltd.GL Pharm Tech Corp. (KOSDAQ:A204840) announced a private placement of series 6 non-guaranteed private equity convertible bonds with registered interest for gross proceeds of KRW 4,500,000,000 on November 23, 2020. The transaction will include participation from Ideal Priavate Equity 1 Co., Ltd. The bonds will have interest rate of 4% and surface to interest rate 2% and will mature on November 29, 2025. The bonds to be issued are 100% convertible into 4,950,495 shares at a price of KRW 909 for 10.49% equity during the period November 30, 2021 to November 29, 2025. The subscription date is November 23, 2020 and payment date is November 30, 2020. The security to be issued in the transaction will be subject to hold period of one year. The transaction has been approved by the board of directors of the company.Is New 90 Day High Low • Oct 30New 90-day low: ₩875The company is down 14% from its price of ₩1,020 on 31 July 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period.お知らせ • Sep 30GL Pharm Tech Corp. announced that it has received KRW 1.000000232 billion in funding from Kyperion Co., Ltd.On September 29, 2020, GL Pharm Tech Corp. (KOSDAQ:A204840) closed the transaction.Is New 90 Day High Low • Sep 24New 90-day low: ₩896The company is down 10.0% from its price of ₩992 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 23% over the same period.お知らせ • Sep 22GL Pharm Tech Corp. announced that it expects to receive KRW 1.000000232 billion in funding from Kyperion Co., Ltd.GL Pharm Tech Corp. (KOSDAQ:A204840) announced a private placement of 1,152,074 common of par value KRW 100 per share, at an issue price of KRW 868 per share for gross proceeds of KRW 1,000,000,232 on September 21, 2020. The transaction will include participation from Kyperion Co., Ltd for all the shares in the transaction. The company will raise the funding through third party allocation method. The total number of shares issued before the transaction is 46,058,145 shares. All securities to be issued in the transaction will be subject to a lock-up period of one year. The transaction was approved by the bard of directors of the company, and is expected to close on September 29, 2020. The securities are issued at 10% per discount.株主還元A204840KR PharmaceuticalsKR 市場7D-4.9%-8.0%-8.2%1Y-28.2%18.0%159.6%株主還元を見る業界別リターン: A204840過去 1 年間で18 % の収益を上げたKR Pharmaceuticals業界を下回りました。リターン対市場: A204840は、過去 1 年間で159.6 % のリターンを上げたKR市場を下回りました。価格変動Is A204840's price volatile compared to industry and market?A204840 volatilityA204840 Average Weekly Movement5.6%Pharmaceuticals Industry Average Movement7.2%Market Average Movement9.3%10% most volatile stocks in KR Market16.5%10% least volatile stocks in KR Market4.9%安定した株価: A204840 、 KR市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: A204840の 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト200233Yong-Il Kimwww.glpt.co.krGL Pharm Tech Corp.は韓国の製薬会社にジェネリック医薬品とインクリメンタリー・モディファイド・ドラッグ（IMD）製剤技術を提供している。同社は胃炎、抗うつ剤、肛門疾患、抗生物質などのIMDを提供している。また、循環器、泌尿器、疼痛、抗感染症、胃疾患、糖尿病、中枢神経系疾患、呼吸器疾患、移植などのジェネリック医薬品も提供している。さらに、ドライアイを対象とした新規化合物の開発にも取り組んでいる。さらに、神経系と感覚器官用のカバリンCR徐放錠とジャンプルイブフェンシロップ、個々の臓器、消化器官、消化性潰瘍治療薬用のジソレン錠、個々の臓器、消化器官の治療と経口用のゲンストリングトロキを提供している。GLファームテック社は2002年に設立され、韓国の城南市に本社を置いている。もっと見るGL Pharm Tech Corp. 基礎のまとめGL Pharm Tech の収益と売上を時価総額と比較するとどうか。A204840 基礎統計学時価総額₩72.12b収益（TTM）-₩131.58m売上高(TTM)₩36.86b2.0xP/Sレシオ-548.1xPER（株価収益率A204840 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A204840 損益計算書（TTM）収益₩36.86b売上原価₩22.32b売上総利益₩14.54bその他の費用₩14.68b収益-₩131.58m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-1.70グロス・マージン39.45%純利益率-0.36%有利子負債／自己資本比率102.6%A204840 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 16:58終値2026/05/21 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋GL Pharm Tech Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 13GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2026GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 257, saemaeul-ro, bundang-gu, gyeonggi-do, seongnam South Korea
分析記事 • Dec 01GL Pharm Tech (KOSDAQ:204840) Has A Somewhat Strained Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Reported Earnings • Nov 12Third quarter 2025 earnings released: EPS: ₩2.00 (vs ₩2.00 loss in 3Q 2024)Third quarter 2025 results: EPS: ₩2.00 (up from ₩2.00 loss in 3Q 2024). Revenue: ₩9.53b (up 104% from 3Q 2024). Net income: ₩132.8m (up ₩250.4m from 3Q 2024). Profit margin: 1.4% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Sep 23GL Pharm Tech Corp.'s (KOSDAQ:204840) P/S Still Appears To Be ReasonableWhen you see that almost half of the companies in the Pharmaceuticals industry in Korea have price-to-sales ratios (or...
New Risk • Aug 27New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 1.1x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risk Market cap is less than US$100m (₩90.2b market cap, or US$64.7m).
Reported Earnings • May 16First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: ₩7.84b (up 34% from 1Q 2024). Net income: ₩24.1m (up ₩1.66b from 1Q 2024). Profit margin: 0.3% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
お知らせ • Mar 13GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2026GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 257, saemaeul-ro, bundang-gu, gyeonggi-do, seongnam South Korea
分析記事 • Dec 01GL Pharm Tech (KOSDAQ:204840) Has A Somewhat Strained Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Reported Earnings • Nov 12Third quarter 2025 earnings released: EPS: ₩2.00 (vs ₩2.00 loss in 3Q 2024)Third quarter 2025 results: EPS: ₩2.00 (up from ₩2.00 loss in 3Q 2024). Revenue: ₩9.53b (up 104% from 3Q 2024). Net income: ₩132.8m (up ₩250.4m from 3Q 2024). Profit margin: 1.4% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Sep 23GL Pharm Tech Corp.'s (KOSDAQ:204840) P/S Still Appears To Be ReasonableWhen you see that almost half of the companies in the Pharmaceuticals industry in Korea have price-to-sales ratios (or...
New Risk • Aug 27New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 1.1x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risk Market cap is less than US$100m (₩90.2b market cap, or US$64.7m).
Reported Earnings • May 16First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: ₩7.84b (up 34% from 1Q 2024). Net income: ₩24.1m (up ₩1.66b from 1Q 2024). Profit margin: 0.3% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
分析記事 • Apr 23Revenues Tell The Story For GL Pharm Tech Corp. (KOSDAQ:204840) As Its Stock Soars 45%The GL Pharm Tech Corp. ( KOSDAQ:204840 ) share price has done very well over the last month, posting an excellent gain...
New Risk • Apr 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩5.0b free cash flow). Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (₩109.2b market cap, or US$76.8m).
Reported Earnings • Mar 22Full year 2024 earnings released: ₩31.00 loss per share (vs ₩60.00 loss in FY 2023)Full year 2024 results: ₩31.00 loss per share (improved from ₩60.00 loss in FY 2023). Revenue: ₩26.0b (flat on FY 2023). Net loss: ₩2.34b (loss narrowed 38% from FY 2023). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 4% per year.
お知らせ • Mar 13GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2025GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 257, saemaeul-ro, bundang-gu, gyeonggi-do, seongnam South Korea
New Risk • Aug 23New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩4.8b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩4.8b free cash flow). Minor Risks Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (₩80.8b market cap, or US$60.4m).
分析記事 • Jul 23Is GL Pharm Tech (KOSDAQ:204840) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Risk • Apr 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩101.2b market cap, or US$73.6m).
New Risk • Mar 30New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩104.5b market cap, or US$77.7m).
Reported Earnings • Mar 21Full year 2023 earnings released: ₩60.00 loss per share (vs ₩13.00 loss in FY 2022)Full year 2023 results: ₩60.00 loss per share (further deteriorated from ₩13.00 loss in FY 2022). Revenue: ₩26.0b (up 56% from FY 2022). Net loss: ₩3.75b (loss widened 374% from FY 2022). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 07W Science Co., Ltd. completed the acquisition of 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity FundW Science Co., Ltd. agreed to acquire a 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity Fund for KRW 15.77 billion on September 14, 2023. W Science Co., Ltd. entered into an agreement to acquire 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity Fund, KAIS Inc and Hoon-sik Wang for KRW 15.77 billion on February 28, 2024. The offer per share is KRW 1700 per share. The scheduled transaction closing date is April 29, 2024. W Science Co., Ltd. completed the acquisition of 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity Fund on March 6, 2024.
お知らせ • Mar 06GL Pharm Tech Corp. announced that it has received KRW 9.199999458 billion in funding from W Science Co., Ltd.On March 6, 2024, GL Pharm Tech Corp. closed the transaction.
分析記事 • Mar 01Market Participants Recognise GL Pharm Tech Corp.'s (KOSDAQ:204840) Revenues Pushing Shares 25% HigherGL Pharm Tech Corp. ( KOSDAQ:204840 ) shares have had a really impressive month, gaining 25% after a shaky period...
Reported Earnings • Nov 15Third quarter 2023 earnings released: ₩15.00 loss per share (vs ₩5.00 loss in 3Q 2022)Third quarter 2023 results: ₩15.00 loss per share (further deteriorated from ₩5.00 loss in 3Q 2022). Revenue: ₩7.69b (up 64% from 3Q 2022). Net loss: ₩963.6m (loss widened 280% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
New Risk • Nov 15New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩3.1b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩3.1b free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (₩78.1b market cap, or US$59.9m).
New Risk • Jul 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩67.7b market cap, or US$52.6m).
Reported Earnings • May 14First quarter 2023 earnings released: ₩10.00 loss per share (vs ₩42.00 loss in 1Q 2022)First quarter 2023 results: ₩10.00 loss per share (improved from ₩42.00 loss in 1Q 2022). Revenue: ₩5.11b (up 103% from 1Q 2022). Net loss: ₩598.2m (loss narrowed 73% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 08Third quarter 2022 earnings released: ₩5.00 loss per share (vs ₩5.00 loss in 3Q 2021)Third quarter 2022 results: ₩5.00 loss per share (in line with 3Q 2021). Revenue: ₩4.70b (up 88% from 3Q 2021). Net loss: ₩306.2m (loss narrowed 78% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
分析記事 • Mar 30Would GL Pharm Tech (KOSDAQ:204840) Be Better Off With Less Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • Dec 15The GL Pharm Tech (KOSDAQ:204840) Share Price Is Up 50% And Shareholders Are Holding OnPassive investing in index funds can generate returns that roughly match the overall market. But one can do better than...
Is New 90 Day High Low • Dec 02New 90-day high: ₩1,190The company is up 17% from its price of ₩1,015 on 03 September 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.
お知らせ • Nov 25GL Pharm Tech Corp. announced that it expects to receive KRW 4.5 billion in funding from Ideal Priavate Equity 1 Co., Ltd.GL Pharm Tech Corp. (KOSDAQ:A204840) announced a private placement of series 6 non-guaranteed private equity convertible bonds with registered interest for gross proceeds of KRW 4,500,000,000 on November 23, 2020. The transaction will include participation from Ideal Priavate Equity 1 Co., Ltd. The bonds will have interest rate of 4% and surface to interest rate 2% and will mature on November 29, 2025. The bonds to be issued are 100% convertible into 4,950,495 shares at a price of KRW 909 for 10.49% equity during the period November 30, 2021 to November 29, 2025. The subscription date is November 23, 2020 and payment date is November 30, 2020. The security to be issued in the transaction will be subject to hold period of one year. The transaction has been approved by the board of directors of the company.
Is New 90 Day High Low • Oct 30New 90-day low: ₩875The company is down 14% from its price of ₩1,020 on 31 July 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period.
お知らせ • Sep 30GL Pharm Tech Corp. announced that it has received KRW 1.000000232 billion in funding from Kyperion Co., Ltd.On September 29, 2020, GL Pharm Tech Corp. (KOSDAQ:A204840) closed the transaction.
Is New 90 Day High Low • Sep 24New 90-day low: ₩896The company is down 10.0% from its price of ₩992 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 23% over the same period.
お知らせ • Sep 22GL Pharm Tech Corp. announced that it expects to receive KRW 1.000000232 billion in funding from Kyperion Co., Ltd.GL Pharm Tech Corp. (KOSDAQ:A204840) announced a private placement of 1,152,074 common of par value KRW 100 per share, at an issue price of KRW 868 per share for gross proceeds of KRW 1,000,000,232 on September 21, 2020. The transaction will include participation from Kyperion Co., Ltd for all the shares in the transaction. The company will raise the funding through third party allocation method. The total number of shares issued before the transaction is 46,058,145 shares. All securities to be issued in the transaction will be subject to a lock-up period of one year. The transaction was approved by the bard of directors of the company, and is expected to close on September 29, 2020. The securities are issued at 10% per discount.
